Bin Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bin Yang has a total of 198 co-authors. Here are the top co-authors by number of shared publications:
- Gang Chen
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
53 shared publications - Xin Jin
BGI-Shenzhen, Shenzhen, China.
45 shared publications - Dijun Chen
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, China
44 shared publications - Wenwei Zhang
BGI-Shenzhen
44 shared publications - Wenxuan Ming
Nanjing University 1 Department of Gastroenterology, Nanjing Drum Tower Hospital, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences Nanjing, China
44 shared publications - Xin Hou
Tongji Hospital 2 Department of Gynecological Oncology Tongji Medical College Wuhan, China
44 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S25 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Spatial feature plots of the distribution and enrichment of the GP2 molecular subtype (differentiated-proliferative) in high-grade serous ovarian carcinoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S25 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Spatial feature plots of the distribution and enrichment of the GP2 molecular subtype (differentiated-proliferative) in high-grade serous ovarian carcinoma
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Western blot analysis of ITGA5 and CD44 expression in HOC7 and SKOV3 cells transfected with specific siRNAs or negative control
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Western blot analysis of ITGA5 and CD44 expression in HOC7 and SKOV3 cells transfected with specific siRNAs or negative control
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Spatial distribution of fibroblasts in high-grade serous ovarian carcinoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Spatial distribution of fibroblasts in high-grade serous ovarian carcinoma
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S32 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Survival analysis of epithelial cell subtypes in high-grade serous ovarian carcinoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S32 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Survival analysis of epithelial cell subtypes in high-grade serous ovarian carcinoma
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Cellular heterogeneity across different anatomical sites
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Cellular heterogeneity across different anatomical sites
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
High-grade serous ovarian cancer (HGSOC) is a lethal malignancy characterized by profound intratumoral heterogeneity and immune evasion. Although previous research has identified 4 molecular subtypes of HGSOC, defining their spatial distribution across anatomic sites could help identify functional mediators of progression and immune evasion. In this study, we performed single-cell and spatial transcriptomic sequencing on 66 anatomically paired samples across 5 sites from 8 patients and conducted an integrated analysis on the generated datasets. Five distinct gene programs (GP) with specific spatial distributions and functional roles were identified: GP1 (differentiated-invasive), GP2 (differentiated-proliferative), GP3 (immunoreactive), GP4 (mesenchymal), and GP5 (proliferative). Interestingly, molecular subtypes exhibited dynamic spatial transitions that promote HGSOC progression. The differentiated-proliferative subtype dominated tumor cores, whereas the differentiated-invasive subtype localized to the invasive front driven by SDC4-expressing epithelial cells (c40) that were functionally validated to promote migration/invasion. Concurrently, immune evasion operated through distinct mechanisms. Differentiated-invasive and immunoreactive subtype co-localization established immunosuppression via the TNFα–SAA1/2–APOE signaling axis that recruits immunosuppressive myeloid cells across primary and metastatic sites, whereas fibroblast-derived collagen barriers were constructed at the interfaces between mesenchymal and immunoreactive subtypes in omental metastases along with dysregulated chemokines to exclude immune infiltration. This spatially resolved atlas directly links subtype spatial transitions to tumor progression and subtype co-localization to immune evasion, providing a mechanistic framework for targeting spatially organized tumor–immune interactions in HGSOC. Significance:Spatially resolved transcriptomic analysis reveals tumor subtype transitions and niche-specific immune evasion mechanisms in ovarian cancer.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
High-grade serous ovarian cancer (HGSOC) is a lethal malignancy characterized by profound intratumoral heterogeneity and immune evasion. Although previous research has identified 4 molecular subtypes of HGSOC, defining their spatial distribution across anatomic sites could help identify functional mediators of progression and immune evasion. In this study, we performed single-cell and spatial transcriptomic sequencing on 66 anatomically paired samples across 5 sites from 8 patients and conducted an integrated analysis on the generated datasets. Five distinct gene programs (GP) with specific spatial distributions and functional roles were identified: GP1 (differentiated-invasive), GP2 (differentiated-proliferative), GP3 (immunoreactive), GP4 (mesenchymal), and GP5 (proliferative). Interestingly, molecular subtypes exhibited dynamic spatial transitions that promote HGSOC progression. The differentiated-proliferative subtype dominated tumor cores, whereas the differentiated-invasive subtype localized to the invasive front driven by SDC4-expressing epithelial cells (c40) that were functionally validated to promote migration/invasion. Concurrently, immune evasion operated through distinct mechanisms. Differentiated-invasive and immunoreactive subtype co-localization established immunosuppression via the TNFα–SAA1/2–APOE signaling axis that recruits immunosuppressive myeloid cells across primary and metastatic sites, whereas fibroblast-derived collagen barriers were constructed at the interfaces between mesenchymal and immunoreactive subtypes in omental metastases along with dysregulated chemokines to exclude immune infiltration. This spatially resolved atlas directly links subtype spatial transitions to tumor progression and subtype co-localization to immune evasion, providing a mechanistic framework for targeting spatially organized tumor–immune interactions in HGSOC. Significance:Spatially resolved transcriptomic analysis reveals tumor subtype transitions and niche-specific immune evasion mechanisms in ovarian cancer.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S27 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Spatial feature plots of the distribution and enrichment of the GP4 molecular subtype (mesenchymal) in high-grade serous ovarian carcinoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S27 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Spatial feature plots of the distribution and enrichment of the GP4 molecular subtype (mesenchymal) in high-grade serous ovarian carcinoma
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S28 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Spatial feature plots of the distribution and enrichment of the GP5 molecular subtype (proliferative) in high-grade serous ovarian carcinoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S28 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Spatial feature plots of the distribution and enrichment of the GP5 molecular subtype (proliferative) in high-grade serous ovarian carcinoma
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Manual annotation of cell subtypes in the single-cell transcriptomic data
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Manual annotation of cell subtypes in the single-cell transcriptomic data
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S15 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Spatial distribution of pericytes in high-grade serous ovarian carcinoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S15 from Spatially Resolved Molecular Subtyping Uncovers Tumor Progression and Immune Evasion Mechanisms in High-grade Serous Ovarian Cancer
Spatial distribution of pericytes in high-grade serous ovarian carcinoma